Combination injection or IV administration
What the study did: The researchers assessed whether receiving the monoclonal antibodies casirivimab and imdevimab by injection was associated with reduced hospitalizations and deaths compared to no treatment in patients with COVID-19 and whether the results were similar if they were administered by injection or intravenously. Administration by injection may increase the capacity for outpatient treatment, but its effectiveness is unknown.
Authors: Erin K. McCreary, Pharm.D., of the University of Pittsburgh School of Medicine, is the corresponding author.
To access the study under embargo: Visit our For Media website at this link https://media.jamanetwork.com/
Editor’s note: Please see the article for more information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers with free access to the full-text article This link will be live at the time of the embargo http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.6920?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041222
On Open JAMA Network: Open JAMA Network is the new online-only open access general medical journal of the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health fields. Each article is put online for free from the day of its publication.
Open JAMA Network
Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.